SOPHARMA AD - Notification for sales revenues for April 2026

Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:

1. SFA_Sales_Revenues_April_2026_EN_espi.pdfNotification for sales revenues for April 2026
   

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 141 / 2026

Date of issue: 2026-05-20

Short name of the issuer

SOPHARMA AD

Subject

Notification for sales revenues for April 2026

Official market - legal basis

Art. 56. 1. 2 of Act on Public Offering

Unofficial market - legal basis

Contents of the report:

Sofia, Bulgaria, May 20, 2026 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that April 2026 the Company recorded an increase in sales of 115% compared to the same month of the previous year, incl. 27% increase in domestic sales and 191% increase in export sales.
For the period from the beginning of 2026, the Company achieved sales growth of 32%, including a 17% decrease in domestic sales and a 61% growth in export sales.

Annexes

File Description

SFA_Sales_Revenues_April_2026_EN_espi.pdfSFA_Sales_Revenues_April_2026_EN_espi.pdf Notification for sales revenues for April 2026

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2026-05-20 Ognian Ivanov Donev Executive Director

20260520_124514_1971519149_SFA_Sales_Revenues_April_2026_EN_espi.pdf

Pobierz